Liquidia Technologies, Inc. is a late stage clinical biopharmaceutical company. The company is engaged in the development of therapeutics utilizing its proprietary PRINT technology. The company’s developmental pipeline includes treatment candidates for pulmonary arterial hypertension (PAH) and local post-operative pain.